Amgen Inc.AMGN
NASDAQ • Healthcare
$357.15
P/E
25.09
PEG
—
FCF Yield
—
Rev Growth YoY
+995.0% YoY
Gross Margin
7330.0%
Health Score
4/10
D/E Ratio
6.31
Confidence
LOW
Business Snapshot
Amgen is one of the world's largest biotechnology companies, operating in the Drug Manufacturers – General industry within the Healthcare sector. The company develops and markets human therapeutics focused on oncology, cardiovascular disease, inflammation, bone health, and nephrology, selling primarily to hospitals, clinics, and pharmacies across global markets. Based on the current price of $357.15 and the available valuation ratios, Amgen is a large-cap enterprise, though a precise market capitalisation figure is not available from the current data payload.
Financial Health
**Score: 4/10** Amgen's financial health picture is sharply contradicted by a handful of headline numbers. On one hand, the gross margin figure of 7,330% and net margin of 2,098% appear implausibly elevated — these are almost certainly the result of data normalisation anomalies or one-time accounting adjustments and should not be taken at face value...
Risk Assessment
- **DEBT:** Debt/equity of 6.31x is extremely high, indicating Amgen carries substantial financial leverage that could amplify downside in an earnings deterioration scenario. - **DATA INTEGRITY:** Gross margin of 7,330% and net margin of 2,098% are implausible at face value and suggest underlying data anomalies, reducing confidence in all margin-derived conclusions. - **CASH FLOW:** Free cash flow is unavailable, making it impossible to assess the company's ability to service its debt load or fund future R&D and capital allocation. - **TECHNICALS:** A confirmed death cross (50-day MA crossing below 200-day MA) is a classically bearish technical signal, and the MACD is also flagged as bearish, suggesting near-term price momentum is negative. - **PRICE POSITIONING:** At $357.15, the stock sits below both its 50-day and 200-day moving averages and is 8.7% below its 52-week high of $391.29, indicating the price trend has been declining. ---...